Published in Am J Pathol on September 01, 1995
Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol (1998) 3.61
Nucleolus, ribosomes, and cancer. Am J Pathol (2008) 2.53
Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev (1997) 2.47
Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res (2008) 2.18
Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol (2001) 2.06
Increase in proliferation and apoptosis of gastric epithelial cells early in the natural history of Helicobacter pylori infection. Am J Pathol (1997) 1.74
The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients. Br J Cancer (2004) 1.71
At the crossroads of inflammation and tumorigenesis. J Exp Med (1999) 1.61
Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol (1999) 1.52
Cyclin D1 and human neoplasia. Mol Pathol (1998) 1.50
Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc Natl Acad Sci U S A (1996) 1.41
A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell (2013) 1.37
Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway. Genes Dev (1998) 1.27
Differential expression of cyclin-dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia. Am J Pathol (1998) 1.24
Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer (1998) 1.19
Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am J Pathol (1998) 1.19
Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients. BMC Gastroenterol (2004) 1.18
Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions: immunocytochemical and quantitative image analyses. Am J Pathol (1997) 1.12
Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas. Am J Pathol (1999) 1.11
Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas. Mol Med (1998) 1.06
p16INK4a hypermethylation and p53, p16 and MDM2 protein expression in esophageal squamous cell carcinoma. BMC Cancer (2010) 1.06
Identification and partial characterization of a novel membrane-associated protein (MAP17) up-regulated in human carcinomas and modulating cell replication and tumor growth. Am J Pathol (1996) 1.05
Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. Am J Pathol (1998) 1.04
Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. Am J Pathol (1999) 1.04
Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol (1999) 1.04
CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations. Am J Pathol (1998) 1.03
Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex. Proc Natl Acad Sci U S A (1997) 1.02
Proteolysis and the biochemistry of life-or-death decisions. J Exp Med (1996) 1.01
Molecular events in uterine cervical cancer. Sex Transm Infect (1998) 1.01
Effects of retinoic acid on proliferation, phenotype and expression of cyclin-dependent kinase inhibitors in TGF-beta1-stimulated rat hepatic stellate cells. World J Gastroenterol (2000) 1.01
Clinical significance of molecular expression profiles of Hürthle cell tumors of the thyroid gland analyzed via tissue microarrays. Am J Pathol (2002) 0.99
Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions. J Clin Pathol (2001) 0.96
Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. Br J Cancer (1997) 0.96
Molecular pathways in bladder cancer. Urol Res (2004) 0.95
Immunohistochemical analysis of non-small cell lung cancer: correlation with clinical parameters and prognosis. J Korean Med Sci (2007) 0.95
Neural-cadherin expression associated with angiogenesis in non-small-cell lung cancer patients. Br J Cancer (2003) 0.95
Spotlight on differentially expressed genes in urinary bladder cancer. PLoS One (2011) 0.94
Molecular aberrations of the G1-S checkpoint in myxoid and round cell liposarcoma. Am J Pathol (1997) 0.94
Retinoblastoma (RB1) gene product expression in breast carcinoma. Correlation with Ki-67 growth fraction and biopathological profile. J Clin Pathol (1998) 0.92
Spatial association of apoptosis-related gene expression and cellular death in clinical neuroblastoma. Br J Cancer (1997) 0.92
Cyclin D1 overexpression related to retinoblastoma protein expression as a prognostic marker in human oesophageal squamous cell carcinoma. Br J Cancer (1998) 0.91
Relationship between proliferative activity of cancer cells and clinicopathological factors in patients with esophageal squamous cell carcinoma. World J Gastroenterol (2005) 0.90
Alterations of cell cycle regulators in localized synovial sarcoma: A multifactorial study with prognostic implications. Am J Pathol (2000) 0.90
Cancer models, genomic instability and somatic cellular Darwinian evolution. Biol Direct (2010) 0.90
The prognostic value of the AgNOR parameter in human breast cancer depends on the pRb and p53 status. J Clin Pathol (2004) 0.89
Tumor suppressors and cell-cycle proteins in lung cancer. Patholog Res Int (2011) 0.89
CDK/CCN and CDKI alterations for cancer prognosis and therapeutic predictivity. Biomed Res Int (2014) 0.88
Cyclin A overexpression is associated with chemosensitivity to paclitaxel-based chemotherapy in patients with esophageal squamous cell carcinoma. Oncol Lett (2012) 0.88
Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival. Br J Cancer (2000) 0.87
Alcohol exposure alters cell cycle and apoptotic events during early neurulation. Alcohol Alcohol (2008) 0.87
X-linked inhibitor of apoptosis protein (XIAP) regulation of cyclin D1 protein expression and cancer cell anchorage-independent growth via its E3 ligase-mediated protein phosphatase 2A/c-Jun axis. J Biol Chem (2013) 0.86
Protein expression profiles indicative for drug resistance of non-small cell lung cancer. Br J Cancer (2002) 0.85
Molecular staging of prostate cancer in the year 2007. World J Urol (2007) 0.85
p16 protein expression is associated with a poor prognosis in squamous cell carcinoma of the lung. Br J Cancer (2000) 0.84
Genetic polymorphisms of p21 and risk of second primary malignancy in patients with index squamous cell carcinoma of the head and neck. Carcinogenesis (2009) 0.84
Inverse correlation between high level expression of cyclin E and proliferation index in transitional cell carcinoma of the bladder. Mol Pathol (2003) 0.83
Clonality as expression of distinctive cell kinetics patterns in nodular hyperplasias and adenomas of the adrenal cortex. Am J Pathol (2000) 0.82
Expression of the cell cycle regulatory proteins p34cdc2, p21waf1, and p53 in node negative invasive ductal breast carcinoma. Mol Pathol (2003) 0.82
Prognostic significance of cyclin E and p53 protein overexpression in carcinoma of the renal pelvis and ureter. Br J Cancer (1998) 0.81
Association between p21 Ser31Arg polymorphism and cancer risk: a meta-analysis. Chin J Cancer (2011) 0.81
Survey of molecular profiling during human colon cancer development and progression by immunohistochemical staining on tissue microarray. World J Gastroenterol (2007) 0.81
New prognostic factors in resectable non-small cell lung cancer. Thorax (1996) 0.81
Proliferation and apoptosis of follicular lymphocytes: relationship to follicular dendritic cell-associated clusters. Immunology (1997) 0.81
The role of the replication licensing system in cell proliferation and cancer. Prog Cell Cycle Res (2003) 0.81
All-trans retinoic acid decreases susceptibility of a gastric cancer cell line to lymphokine-activated killer cytotoxicity. Br J Cancer (1997) 0.81
Different apoptotic activity and p21(WAF1/CIP1), but not p27(Kip1), expression in serrated adenomas as compared with traditional adenomas and hyperplastic polyps of the colorectum. J Cancer Res Clin Oncol (2003) 0.80
Immunohistochemical evaluation of oral epithelial dysplasia using cyclin-D1, p27 and p63 expression as predictors of malignant transformation. J Nat Sci Biol Med (2013) 0.80
Prognostic significance of P27 (Kip 1) and MUC1 in papillary transitional cell carcinoma of the urinary bladder. Urol Ann (2011) 0.80
Frequent p16INK4 (MTS1) gene inactivation in testicular germ cell tumors. Am J Pathol (1997) 0.80
Genes involved in cell cycle G1 checkpoint control are frequently mutated in human melanoma metastases. Br J Cancer (1996) 0.79
Overexpression of bax associated with mutations in the loop-sheet-helix motif of p53. Am J Pathol (1999) 0.79
The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway. Cancer Prev Res (Phila) (2012) 0.79
Clinicopathological significance of pRb2/p130 expression in squamous cell carcinoma of the esophagus. J Cancer Res Clin Oncol (2002) 0.78
Association between nm23-H1 expression, proliferation and apoptosis in non-small cell lung carcinomas. Clin Exp Metastasis (1998) 0.78
Overexpression of Lin28 Decreases the Chemosensitivity of Gastric Cancer Cells to Oxaliplatin, Paclitaxel, Doxorubicin, and Fluorouracil in Part via microRNA-107. PLoS One (2015) 0.77
Overexpression of p18INK⁴C in LLC-PK1 cells increases resistance to cisplatin-induced apoptosis. Pediatr Nephrol (2011) 0.77
Expression of altered retinoblastoma protein inversely correlates with tumor invasion in gastric carcinoma. World J Gastroenterol (2006) 0.77
Loss of p16INK4A expression is associated with allelic imbalance/loss of heterozygosity of chromosome 9p21 in microdissected synovial sarcomas. Virchows Arch (2005) 0.77
Molecular and immunopathology studies of oncogenes and tumor-suppressor genes in bladder cancer. World J Urol (1997) 0.76
Genetics and pulmonary medicine. 7. Somatic mutations in the development of lung cancer. Thorax (1998) 0.76
Expression patterns of cyclin E, cyclin A and CDC25 phosphatases in laryngeal carcinogenesis. Eur Arch Otorhinolaryngol (2007) 0.76
New advances in the molecular biology of musculoskeletal neoplasms. Iowa Orthop J (1997) 0.76
Anti-cancer Activity of Osmanthus matsumuranus Extract by Inducing G2/M Arrest and Apoptosis in Human Hepatocellular Carcinoma Hep G2 Cells. J Cancer Prev (2015) 0.76
Cell proliferation of esophageal squamous epithelium in erosive and non-erosive reflux disease. World J Gastroenterol (2011) 0.75
Expression of p53, Ki67, epidermal growth factor receptor, transforming growth-factorα, and p21 in primary and secondary hyperparathyroidism. Indian J Endocrinol Metab (2014) 0.75
Serum microRNA-30c levels are correlated with disease progression in Xinjiang Uygur patients with chronic hepatitis B. Braz J Med Biol Res (2017) 0.75
WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 38.72
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell (1993) 33.20
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (1992) 25.54
Universal control mechanism regulating onset of M-phase. Nature (1990) 19.11
Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (1992) 17.40
Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (1990) 16.68
The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science (1989) 16.54
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell (1992) 16.53
Participation of p53 protein in the cellular response to DNA damage. Cancer Res (1991) 16.00
p21 is a universal inhibitor of cyclin kinases. Nature (1993) 15.55
Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell (1979) 14.05
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (1993) 13.68
Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (1994) 13.51
A cell cycle regulator potentially involved in genesis of many tumor types. Science (1994) 13.00
Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science (1990) 12.88
SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell (1988) 12.69
Tyrosine phosphorylation of the fission yeast cdc2+ protein kinase regulates entry into mitosis. Nature (1989) 11.90
G1 phase progression: cycling on cue. Cell (1994) 11.62
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res (1994) 11.29
Effects of an Rb mutation in the mouse. Nature (1992) 11.06
Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature (1988) 10.98
p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature (1994) 10.95
Cell cycle control and cancer. Science (1994) 10.90
Cyclin: a protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell (1983) 9.90
The E2F transcription factor is a cellular target for the RB protein. Cell (1991) 9.62
Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell (1994) 9.48
Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell (1982) 9.27
Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell (1994) 9.25
p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell (1994) 8.90
p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev (1994) 8.52
A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature (1991) 7.98
An essential G1 function for cyclin-like proteins in yeast. Cell (1989) 7.43
Activation of cdc2 protein kinase during mitosis in human cells: cell cycle-dependent phosphorylation and subunit rearrangement. Cell (1988) 6.88
Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature (1993) 6.84
Cytoplasmic control of nuclear behavior during meiotic maturation of frog oocytes. J Exp Zool (1971) 6.83
Oncogenic forms of p53 inhibit p53-regulated gene expression. Science (1992) 6.73
The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell (1989) 6.68
Identification of cellular proteins that can interact specifically with the T/E1A-binding region of the retinoblastoma gene product. Cell (1991) 6.55
Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell (1989) 6.46
The Xenopus cdc2 protein is a component of MPF, a cytoplasmic regulator of mitosis. Cell (1988) 6.45
The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell (1989) 6.43
Presence of a potent transcription activating sequence in the p53 protein. Science (1990) 6.38
Identification of a cellular transcription factor involved in E1A trans-activation. Cell (1986) 6.36
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (1994) 6.06
Germline p16 mutations in familial melanoma. Nat Genet (1994) 5.59
Retinoblastoma protein switches the E2F site from positive to negative element. Nature (1992) 5.47
Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci U S A (1989) 5.40
Mitosis in transition. Cell (1994) 5.03
Cyclin is a component of maturation-promoting factor from Xenopus. Cell (1990) 4.70
Structural evidence for the authenticity of the human retinoblastoma gene. Science (1987) 4.67
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet (1994) 4.63
p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature (1994) 4.52
Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst (1993) 4.45
Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med (1994) 4.34
Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J (1991) 4.33
Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev (1994) 4.30
Ordering S phase and M phase in the cell cycle. Cell (1994) 3.87
Purification of maturation-promoting factor, an intracellular regulator of early mitotic events. Proc Natl Acad Sci U S A (1988) 3.74
Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein. Proc Natl Acad Sci U S A (1987) 3.72
Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev (1993) 3.70
Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res (1994) 3.65
Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science (1984) 3.64
Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science (1990) 3.58
Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res (1994) 3.54
Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev (1992) 3.37
Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci U S A (1990) 3.20
Cloning of cDNAs for cellular proteins that bind to the retinoblastoma gene product. Nature (1991) 3.20
Contiguous gene syndromes: a component of recognizable syndromes. J Pediatr (1986) 3.18
Driving the cell cycle: M phase kinase, its partners, and substrates. Cell (1990) 3.06
Deletion of p16 and p15 genes in brain tumors. Cancer Res (1994) 3.03
The role of p34 kinases in the G1 to S-phase transition. Annu Rev Cell Biol (1992) 3.02
G1/S phosphorylation of the retinoblastoma protein is associated with an altered affinity for the nuclear compartment. Cell (1991) 2.87
Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A (1993) 2.85
Second nonocular tumors in retinoblastoma survivors. Are they radiation-induced? Ophthalmology (1984) 2.82
Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst (1992) 2.82
Genetic alterations in bladder cancer. Lancet (1993) 2.73
Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet (1994) 2.73
Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst (1993) 2.66
Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med (1992) 2.64
Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med (1992) 2.59
Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol Biol Cell (1993) 2.57
p16 gene in uncultured tumours. Nature (1994) 2.47
Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci U S A (1985) 2.44
Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst (1969) 2.30
CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res (1994) 2.28
DNA polymorphism and molecular pathology of the human globin gene clusters. Hum Genet (1985) 2.09
PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci U S A (1991) 2.04
Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumors. Cancer (1990) 2.00
p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res (1995) 1.95
Reproducibility of a histopathologic grading system for adult soft tissue sarcoma. Cancer (1986) 1.88
Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4. Cancer Res (1994) 1.88
Cyclin E, a potential prognostic marker for breast cancer. Cancer Res (1994) 1.82
Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst (1992) 1.81
Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res (1994) 1.80
CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res (1994) 1.76
Chromosome 11q13 abnormalities in human cancer. Cancer Cells (1991) 1.74
Formation of stable p53 homotetramers and multiples of tetramers. Mol Carcinog (1992) 1.68
Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res (1995) 1.67
Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest (1989) 1.64
Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res (1994) 1.51
Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res (1997) 1.35